Drug Profile
Research programme: beta-glucuronidase inhibitors - Southeast TechInventures
Alternative Names: GUS inhibitors - Southeast TechInventuresLatest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator Southeast TechInventures
- Class
- Mechanism of Action Glucuronidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Diarrhoea
Highest Development Phases
- No development reported Diarrhoea
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for research development in Diarrhoea(Prevention, Chemotherapy-induced) in USA
- 11 Aug 2016 Research programme: beta-glucuronidase inhibitors - Southeast TechInventures is available for licensing as of 11 Aug 2016. http://www.setechinv.com/index.php
- 11 Aug 2016 Early research in Diarrhoea (Chemotherapy-induced, Prevention) in USA (unspecified route)